Here's Why AC Immune Stock Is Surging Today
Shares of AC Immune (NASDAQ: ACIU), a clinical-stage biopharmaceutical company, are exploding higher in response to clinical trial results. Investors excited about the company's Alzheimer's disease candidate drove the stock 50.1% higher as of 10:35 a.m. EDT on Tuesday.
AC Immune doesn't have any drugs to sell at the moment, so anything that affects the outlook for its lead candidate, semorinemab, will result in dramatic price swings. This biotech stock is shooting through the roof today thanks to phase 2 clinical trial data that was positive, but not entirely.
Image source: Getty Images.
Source Fool.com
